# Metanx Effects on Nerve Fiber Density in Neuropathic Diabetics

> **NCT01503892** · NA · UNKNOWN · sponsor: **St. Luke's Hospital and Health Network, Pennsylvania** · enrollment: 100 (estimated)

## Conditions studied

- Diabetes
- Peripheral Neuropathy

## Interventions

- **DIETARY_SUPPLEMENT:** Metanx
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01503892
- **Lead sponsor:** St. Luke's Hospital and Health Network, Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-12
- **Primary completion:** 2013-10
- **Final completion:** —
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2012-07-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01503892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01503892, "Metanx Effects on Nerve Fiber Density in Neuropathic Diabetics". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01503892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*